Home > Publications Database > Recent advances in cancer immunotherapy. > print

001     163304
005     20240322115504.0
024 7 _ |a 1868-8497
|2 ISSN
024 7 _ |a 10.1007/s12672-021-00422-9
|2 doi
024 7 _ |a pmid:35201440
|2 pmid
024 7 _ |a pmc:PMC8777500
|2 pmc
024 7 _ |a altmetric:112724111
|2 altmetric
024 7 _ |a 1868-8500
|2 ISSN
024 7 _ |a 2730-6011
|2 ISSN
037 _ _ |a DZNE-2022-00084
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Sun, Qiang
|0 0000-0001-8094-2214
|b 0
245 _ _ |a Recent advances in cancer immunotherapy.
260 _ _ |a [New York]
|c 2021
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1711022460_32502
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a Journal: Discover Oncology, ISSN: 2730-6011
520 _ _ |a Cancer immunotherapy represents a major advance in the cure of cancer following the dramatic advancements in the development and refinement of chemotherapies and radiotherapies. In the recent decades, together with the development of early diagnostic techniques, immunotherapy has significantly contributed to improving the survival of cancer patients. The immune-checkpoint blockade agents have been proven effective in a significant fraction of standard therapy refractory patients. Importantly, recent advances are providing alternative immunotherapeutic tools that could help overcome their limitations. In this mini review, we provide an overview on the main steps of the discovery of classic immune-checkpoint blockade agents and summarise the most recent development of novel immunotherapeutic strategies, such as tumour antigens, bispecific antibodies and TCR-engineered T cells.
536 _ _ |a 351 - Brain Function (POF4-351)
|0 G:(DE-HGF)POF4-351
|c POF4-351
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Cancer immunotherapy
|2 Other
650 _ 7 |a Cancer survival
|2 Other
650 _ 7 |a Immune check point blockade
|2 Other
650 _ 7 |a KRas
|2 Other
650 _ 7 |a T cell receptor
|2 Other
650 _ 7 |a p53
|2 Other
700 1 _ |a Melino, Gerry
|0 P:(DE-2719)9001390
|b 1
|u dzne
700 1 _ |a Amelio, Ivano
|0 0000-0003-0739-325X
|b 2
700 1 _ |a Jiang, Jingting
|0 0000-0002-3128-9762
|b 3
700 1 _ |a Wang, Ying
|0 0000-0002-2571-9367
|b 4
700 1 _ |a Shi, Yufang
|0 0000-0001-8964-319X
|b 5
773 _ _ |a 10.1007/s12672-021-00422-9
|g Vol. 12, no. 1, p. 27
|0 PERI:(DE-600)3059869-2
|n 1
|p 27
|t Discover oncology
|v 12
|y 2021
|x 1868-8497
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/163304/files/DZNE-2022-00084.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/163304/files/DZNE-2022-00084.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:163304
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9001390
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-351
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Brain Function
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2022-11-29
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2021-07-21T15:23:25Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-07-21T15:23:25Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-29
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-29
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2022-11-29
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-07-21T15:23:25Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-29
920 1 _ |0 I:(DE-2719)5000018
|k AG Nicotera
|l Synaptic Connectivity and Neurodegeneration
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)5000018
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21